nysenvs
Supply shortages have complicated the pharmaceutical industry.Eli Lilly & Co are making the right pivots.New partnerships aimed at new products show great promise.The dividend is healthy, and long-term growth looks good.5 stocks we like better than Eli Lilly andHeading into the week before Christmas, the United States Food and Drug Administration flagged Eli Lilly & Co. (NYSE:LLY) for a shortage of their new diabetes drug, Mounjaro. They are also having supply issues with their previous diabetes medicine, Trulicity, which is the pharmaceutical company’s best-selling drug of all time. Q3 2022 h...
ValueWalk
Following is the unofficial transcript of a CNBC exclusive interview with Novartis (NYSE:NVS) CEO Dr. Vas Narasimhan on CNBC’s “Squawk on the Street” (M-F 9AM – 11AM ET) today, Wednesday, January 12. Following is a link to video on CNBC.com: Q4 2021 hedge fund letters, conferences and more Novartis CEO: We’re Moving Toward Filing Covid Drug From Molecular Partners With FDACARL QUINTANILLA: Day three of the JPMorgan Healthcare Conference. Meg Tirrell joins us with a special guest. Hey Meg. MEG TIRRELL: Hey Carl. Dr. Vas Narasimhan, the CEO of Novartis, joins us now. Vas, it’s great to see you. ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら